<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144637</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-013</org_study_id>
    <nct_id>NCT01144637</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and
      safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in
      healthy, vaccinia-naïve subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRNT GMT</measure>
    <time_frame>2 weeks following the second vaccination</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT</measure>
    <time_frame>2 weeks following the second vaccination</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT Seroconversion Rate</measure>
    <time_frame>2 weeks following the second vaccination</time_frame>
    <description>Seroconversion rate based on Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA Seroconversion Rate</measure>
    <time_frame>2 weeks following the second vaccination</time_frame>
    <description>Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation PRNT vs ELISA Titers</measure>
    <time_frame>2 weeks following the second vaccination</time_frame>
    <description>Pearson Correlation Coefficient between the log10 transformed PRNT titers and the log10 transformed ELISA titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>within 30 weeks</time_frame>
    <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Signs or Symptoms</measure>
    <time_frame>within 30 weeks</time_frame>
    <description>Incidence, relationship and intensity of any cardiac sign or symptom indicating a case of myo-/pericarditis (Adverse Event of Special Interest (AESI)).
An AESI was defined in this trial as:
Any cardiac sign or symptom developed since the first vaccination
ECG changes determined to be clinically significant
Cardiac enzyme Troponin I &gt;= 2 x ULN (&gt;= Grade 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Grade &gt;=3 Adverse Events</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Incidence of any Grade &gt;=3 Adverse Events probably, possibly or definitely related to the trial vaccine. Pooled solicited (general only) and unsolicited AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Non-serious AEs: Intensity</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Occurrence of unsolicited non-serious AEs by Intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Non-serious AEs: Relationship to Vaccination</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Occurrence of unsolicited non-serious AEs by relationship to study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Local AEs</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Incidence and intensity of solicited local AEs (redness, swelling, induration, pruritus and pain). Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited General AEs</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Incidence of solicited general AEs (pyrexia, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4005</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE®</intervention_name>
    <description>0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>IMVANEX</other_name>
    <other_name>MVA-BN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 ml TBS</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Tris-buffered-saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, 18 to 40 years of age

          -  The subject has read, signed and dated the informed consent form, having been advised
             of the risks and benefits of the trial in a language understood by the subject and
             prior to performance of any trial specific procedures

          -  BMI ≥ 18.5 and &lt; 35

          -  Women of childbearing potential (WOCBP) must have used an acceptable method of
             contraception for 30 days prior to the first vaccination, must agree to use an
             acceptable method of contraception during the trial, and must avoid becoming pregnant
             for at least 28 days after the last vaccination. A woman is considered of childbearing
             potential unless post-menopausal or with a history of hysterectomy (Acceptable
             contraception methods are restricted to abstinence, barrier contraceptives,
             intrauterine contraceptive devices or licensed hormonal products)

          -  WOCBP must have a negative serum pregnancy test at screening and a negative urine
             pregnancy test within 24 hours prior to each vaccination

          -  White blood cells ≥ 2,500/mm3 &lt; ULN

          -  Absolute neutrophil count (ANC) within normal limits

          -  Hemoglobin within normal limits

          -  Platelets within normal limits

          -  Adequate renal function defined as a calculated Creatinine Clearance (CrCl) &gt; 60
             ml/min as estimated by the Cockcroft-Gault equation:

               -  For men: (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg/dl
                  x 72) = CrCl (ml/min)

               -  For women: multiply the result by 0.85 = CrCl (ml/min).

          -  Adequate hepatic function defined as:

               -  a. Total bilirubin ≤ 1.5 x ULN in the absence of other evidence of significant
                  liver disease

               -  b. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline
                  phosphatase ≤ 1.5 x ULN

          -  Troponin I &lt; 2 x ULN

          -  Electrocardiogram (ECG) without clinically significant findings (e.g. any kind of
             atrioventricular or intraventricular conditions or blocks such as complete left or
             right bundle branch block, AV node block, QTc or PR prolongation, premature atrial
             contractions or other atrial arrhythmia, sustained ventricular arrhythmia, two
             premature ventricular contractions in a row, ST elevation consistent with ischemia)

        Exclusion criteria

          -  Typical vaccinia scar

          -  Known or suspected history of smallpox vaccination

          -  History of vaccination with any poxvirus-based vaccine

          -  US Military service prior to 1991 or after January 2003

          -  Pregnant or breast-feeding women

          -  Uncontrolled serious infection, i.e. not responding to antimicrobial therapy

          -  History of any serious medical condition, which in the opinion of the investigator
             would compromise the safety of the subject or would limit the subject's ability to
             complete the trial

          -  History of or active autoimmune disease, persons with vitiligo or thyroid disease
             taking thyroid replacement are not excluded

          -  Known or suspected impairment of immunologic function including, but not limited to,
             HIV Infection, clinically significant liver disease (including chronic active HBV or
             HCV), diabetes mellitus, moderate to severe kidney impairment

          -  History of malignancy other than squamous cell or basal cell skin cancer, unless there
             has been surgical excision that is considered to have achieved cure. Subjects with
             history of skin cancer must not be vaccinated at the previous tumor site

          -  History or clinical manifestation of clinically significant and severe hematological,
             pulmonary, central nervous, cardiovascular or gastrointestinal disorders

          -  Clinically significant mental disorder not adequately controlled by medical treatment

          -  History of coronary heart disease, myocardial infarction, angina pectoris, congestive
             heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high
             blood pressure, or any other heart condition under the care of a doctor

          -  Known history of an immediate family member (father, mother, brother, or sister) who
             has had onset of ischemic heart disease before age 50 years

          -  Ten percent or greater risk of developing a myocardial infarction or coronary death
             within the next 10 years using the National Cholesterol Education Program's risk
             assessment tool (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof) NOTE:
             This criterion applies only to subjects 20 years of age and older

          -  Active or history of chronic alcohol abuse and/or intravenous and/or nasal drug abuse
             (within the past 6 months)

          -  Known allergy to IMVAMUNE® vaccine and its constituents, e.g. tris
             (hydroxymethyl)-amino methane, including know allergy to egg or aminoglycosides

          -  History of anaphylaxis or severe allergic reaction to any vaccine

          -  Acute disease (illness with or without a fever) at the time enrollment

          -  Body temperature ≥100.4°F (≥38.0°C) at the time of enrollment

          -  Having received any vaccinations or planned vaccinations with a live vaccine within 30
             days prior to or after trial vaccination

          -  Having received any vaccinations or planned vaccinations with a killed vaccine within
             14 days prior to or after trial vaccination

          -  Chronic systemic administration (defined as more than 14 days) of &gt; 5 mg prednisone
             (or equivalent)/day or any other immune-modifying drugs during a period starting from
             three months prior to administration of the vaccine and ending at last physical trial
             visit (V5)

          -  Post organ transplant subjects whether or not receiving chronic immunosuppressive
             therapy

          -  Administration or planned administration of immunoglobulins and/or any blood products
             during a period starting from three months prior to administration of the vaccine and
             ending at last physical trial visit (V5)

          -  Use of any investigational or non-registered drug or vaccine other than the trial
             vaccine within 30 days preceding the first dose of the trial vaccine, or planned
             administration of such a drug during the trial period

          -  Trial personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Turner Overton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Infectious Diseases University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine Research Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Clinical Research Center (NCCRC)</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, Inc.</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis, School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS Bio-Kinetic</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Practice Center of Wooster</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Research Group, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physicians Internal Medicine University Physicians &amp; Surgeons, Inc.</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <results_first_submitted>December 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2019</results_first_posted>
  <last_update_submitted>December 7, 2018</last_update_submitted>
  <last_update_submitted_qc>December 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="999"/>
                <participants group_id="P2" count="1005"/>
                <participants group_id="P3" count="999"/>
                <participants group_id="P4" count="1002"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="925"/>
                <participants group_id="P2" count="929"/>
                <participants group_id="P3" count="939"/>
                <participants group_id="P4" count="946"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="999"/>
            <count group_id="B2" value="1005"/>
            <count group_id="B3" value="999"/>
            <count group_id="B4" value="1002"/>
            <count group_id="B5" value="4005"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="6.28"/>
                    <measurement group_id="B2" value="27.5" spread="6.24"/>
                    <measurement group_id="B3" value="28.0" spread="6.31"/>
                    <measurement group_id="B4" value="27.7" spread="6.38"/>
                    <measurement group_id="B5" value="27.7" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="526"/>
                    <measurement group_id="B2" value="527"/>
                    <measurement group_id="B3" value="494"/>
                    <measurement group_id="B4" value="539"/>
                    <measurement group_id="B5" value="2086"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="473"/>
                    <measurement group_id="B2" value="478"/>
                    <measurement group_id="B3" value="505"/>
                    <measurement group_id="B4" value="463"/>
                    <measurement group_id="B5" value="1919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PRNT GMT</title>
        <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>2 weeks following the second vaccination</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT GMT</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="628"/>
                <count group_id="O3" value="641"/>
                <count group_id="O4" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.7" lower_limit="103.4" upper_limit="118.4"/>
                    <measurement group_id="O2" value="100.5" lower_limit="93.7" upper_limit="107.8"/>
                    <measurement group_id="O3" value="117.2" lower_limit="109.0" upper_limit="126.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margins to show that the 3 vaccine lots are equivalent in terms of PRNT GMTs at Week 6 was predefined as [0.5; 2] for the GMT ratios (pairwise)</non_inferiority_desc>
            <param_type>GMT ratio (Group 1 / Group 2)</param_type>
            <param_value>1.1012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9992</ci_lower_limit>
            <ci_upper_limit>1.2136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margins to show that the 3 vaccine lots are equivalent in terms of PRNT GMTs at Week 6 was predefined as [0.5; 2] for the GMT ratios (pairwise)</non_inferiority_desc>
            <param_type>GMT ratio (Group 1 / Group 3)</param_type>
            <param_value>0.9444</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8554</ci_lower_limit>
            <ci_upper_limit>1.0427</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margins to show that the 3 vaccine lots are equivalent in terms of PRNT GMTs at Week 6 was predefined as [0.5; 2] for the GMT ratios (pairwise)</non_inferiority_desc>
            <param_type>GMT ratio (Group 2 / Group 3)</param_type>
            <param_value>0.8577</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7753</ci_lower_limit>
            <ci_upper_limit>0.9488</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT</title>
        <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>2 weeks following the second vaccination</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="628"/>
                <count group_id="O3" value="641"/>
                <count group_id="O4" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="901.0" lower_limit="844.8" upper_limit="961.1"/>
                    <measurement group_id="O2" value="794.4" lower_limit="738.1" upper_limit="855.0"/>
                    <measurement group_id="O3" value="946.7" lower_limit="888.2" upper_limit="1008.9"/>
                    <measurement group_id="O4" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT Seroconversion Rate</title>
        <description>Seroconversion rate based on Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>2 weeks following the second vaccination</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT Seroconversion Rate</title>
          <description>Seroconversion rate based on Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (2) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="628"/>
                <count group_id="O3" value="641"/>
                <count group_id="O4" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.8" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="1.4" lower_limit="0.6" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA Seroconversion Rate</title>
        <description>Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>2 weeks following the second vaccination</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Seroconversion Rate</title>
          <description>Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="628"/>
                <count group_id="O3" value="641"/>
                <count group_id="O4" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.6" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.4" upper_limit="100.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.1" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation PRNT vs ELISA Titers</title>
        <description>Pearson Correlation Coefficient between the log10 transformed PRNT titers and the log10 transformed ELISA titers</description>
        <time_frame>2 weeks following the second vaccination</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation PRNT vs ELISA Titers</title>
          <description>Pearson Correlation Coefficient between the log10 transformed PRNT titers and the log10 transformed ELISA titers</description>
          <population>Per-protocol Set</population>
          <units>Pearson correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="628"/>
                <count group_id="O3" value="641"/>
                <count group_id="O4" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.581" lower_limit="0.527" upper_limit="0.630"/>
                    <measurement group_id="O2" value="0.620" lower_limit="0.569" upper_limit="0.666"/>
                    <measurement group_id="O3" value="0.612" lower_limit="0.561" upper_limit="0.658"/>
                    <measurement group_id="O4" value="0.486" lower_limit="0.424" upper_limit="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE)</description>
        <time_frame>within 30 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE)</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="999"/>
                <count group_id="O2" value="1005"/>
                <count group_id="O3" value="999"/>
                <count group_id="O4" value="1002"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE with intensity &gt;= Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE assessed as related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Signs or Symptoms</title>
        <description>Incidence, relationship and intensity of any cardiac sign or symptom indicating a case of myo-/pericarditis (Adverse Event of Special Interest (AESI)).
An AESI was defined in this trial as:
Any cardiac sign or symptom developed since the first vaccination
ECG changes determined to be clinically significant
Cardiac enzyme Troponin I &gt;= 2 x ULN (&gt;= Grade 2)</description>
        <time_frame>within 30 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Signs or Symptoms</title>
          <description>Incidence, relationship and intensity of any cardiac sign or symptom indicating a case of myo-/pericarditis (Adverse Event of Special Interest (AESI)).
An AESI was defined in this trial as:
Any cardiac sign or symptom developed since the first vaccination
ECG changes determined to be clinically significant
Cardiac enzyme Troponin I &gt;= 2 x ULN (&gt;= Grade 2)</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="999"/>
                <count group_id="O2" value="1005"/>
                <count group_id="O3" value="999"/>
                <count group_id="O4" value="1002"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AESI with intensity &gt;= Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AESI assessed as related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Grade &gt;=3 Adverse Events</title>
        <description>Incidence of any Grade &gt;=3 Adverse Events probably, possibly or definitely related to the trial vaccine. Pooled solicited (general only) and unsolicited AEs</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Related Grade &gt;=3 Adverse Events</title>
          <description>Incidence of any Grade &gt;=3 Adverse Events probably, possibly or definitely related to the trial vaccine. Pooled solicited (general only) and unsolicited AEs</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="999"/>
                <count group_id="O2" value="1005"/>
                <count group_id="O3" value="999"/>
                <count group_id="O4" value="1002"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited Non-serious AEs: Intensity</title>
        <description>Occurrence of unsolicited non-serious AEs by Intensity</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Unsolicited Non-serious AEs: Intensity</title>
          <description>Occurrence of unsolicited non-serious AEs by Intensity</description>
          <population>Full Analysis Set</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="999"/>
                <count group_id="O2" value="1005"/>
                <count group_id="O3" value="999"/>
                <count group_id="O4" value="1002"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="350"/>
                    <measurement group_id="O3" value="320"/>
                    <measurement group_id="O4" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="218"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited Non-serious AEs: Relationship to Vaccination</title>
        <description>Occurrence of unsolicited non-serious AEs by relationship to study vaccine</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Unsolicited Non-serious AEs: Relationship to Vaccination</title>
          <description>Occurrence of unsolicited non-serious AEs by relationship to study vaccine</description>
          <population>Full Analysis Set</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="999"/>
                <count group_id="O2" value="1005"/>
                <count group_id="O3" value="999"/>
                <count group_id="O4" value="1002"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unrelated/None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="218"/>
                    <measurement group_id="O3" value="181"/>
                    <measurement group_id="O4" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="350"/>
                    <measurement group_id="O3" value="320"/>
                    <measurement group_id="O4" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited Local AEs</title>
        <description>Incidence and intensity of solicited local AEs (redness, swelling, induration, pruritus and pain). Percentages based on subjects with at least one completed diary card.</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local AEs</title>
          <description>Incidence and intensity of solicited local AEs (redness, swelling, induration, pruritus and pain). Percentages based on subjects with at least one completed diary card.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="985"/>
                <count group_id="O2" value="976"/>
                <count group_id="O3" value="982"/>
                <count group_id="O4" value="980"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="846"/>
                    <measurement group_id="O2" value="823"/>
                    <measurement group_id="O3" value="830"/>
                    <measurement group_id="O4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="597"/>
                    <measurement group_id="O2" value="610"/>
                    <measurement group_id="O3" value="581"/>
                    <measurement group_id="O4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508"/>
                    <measurement group_id="O2" value="513"/>
                    <measurement group_id="O3" value="499"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454"/>
                    <measurement group_id="O2" value="439"/>
                    <measurement group_id="O3" value="442"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430"/>
                    <measurement group_id="O2" value="424"/>
                    <measurement group_id="O3" value="414"/>
                    <measurement group_id="O4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited General AEs</title>
        <description>Incidence of solicited general AEs (pyrexia, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited General AEs</title>
          <description>Incidence of solicited general AEs (pyrexia, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="985"/>
                <count group_id="O2" value="976"/>
                <count group_id="O3" value="982"/>
                <count group_id="O4" value="980"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pyrexia: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O2" value="349"/>
                    <measurement group_id="O3" value="354"/>
                    <measurement group_id="O4" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279"/>
                    <measurement group_id="O2" value="314"/>
                    <measurement group_id="O3" value="318"/>
                    <measurement group_id="O4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425"/>
                    <measurement group_id="O2" value="403"/>
                    <measurement group_id="O3" value="431"/>
                    <measurement group_id="O4" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404"/>
                    <measurement group_id="O2" value="381"/>
                    <measurement group_id="O3" value="414"/>
                    <measurement group_id="O4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="158"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                    <measurement group_id="O2" value="303"/>
                    <measurement group_id="O3" value="287"/>
                    <measurement group_id="O4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="279"/>
                    <measurement group_id="O3" value="267"/>
                    <measurement group_id="O4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
IMVAMUNE®: 0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
Placebo: 0.5 ml TBS</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1002"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="999"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1005"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="999"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1002"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Lead, Clinical Operations</name_or_title>
      <organization>Bavarian Nordic A/S</organization>
      <phone>+45 3326 ext 8383</phone>
      <email>info@bavarian-nordic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

